1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bangi Inc.

Bangi Inc.

BNGI
Bangi Inc.US flagOther OTC
0.00
USD
- -
- -
5,254.00Market Cap
Bangi Inc.
BNGI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
2010
2011
TTM
FRC
1.82
0.46
0.76
- -
- -
- -
- -
- -
Revenue per Share
0.13
- -
- -
-0.93
-0.64
-0.16
-0.14
-0.08
Basic EPS, GAAP
1.12
- -
0.04
-0.9
-0.39
-0.09
-0.03
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.13
0.01
0.01
-0.89
-1.56
-0.88
-0.32
- -
Book Value per Share
0.12
0.04
0.04
0.44
-0.04
-0.04
-0.04
-0.04
Tangible Book Value per Share
- -
2
2
1
1
2
11
21
Basic Weighted Avg Shares
- -
1
1
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
13.49
1.44
-1.04
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-1
- -
-1
-2
Net Income, GAAP
48.61
55.73
77
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.93
0.66
0.1
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
1
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
48.91
7.12
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Apr'12
Jul'12
Oct'12
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
22
24
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Apr'12
Jul'12
Oct'12
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-305.76%
-52.77%
Free Cash Flow
- -
-644.48%
79.18%
Net Income, GAAP
- -
-13,409.31%
336.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Oxurion N.V. (TBGNF)
Monopar Therapeutics Inc. (MNPR)
Bionomics Limited (BNOX)
Hepion Pharmaceuticals, Inc. (HEPA)
Oncoinvent ASA (ONCIN.OL)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
Business
Bangi Inc. (BNGI) acquires and leases specialized real estate assets to the cannabis industry; its portfolio includes hemp and cannabis farms, dispensaries, and commercial and industrial properties tailored for state-licensed operators. The company, founded in 2004 and headquartered at 18530 Mack Avenue in Grosse Pointe Farms, Michigan, operates as a subsidiary of Bangi Investments, LLC, focusing on sale-leaseback transactions and third-party purchases to address financing gaps caused by federal banking restrictions on cannabis-related businesses. Bangi targets the U.S. cannabis sector, serving experienced, regulated growers, retailers, and extractors with long-term leases that provide asset security and appreciation potential. In recent years, Bangi has pursued strategic expansions including a 2019 strategic alliance with Transatlantic Real Estate to enhance acquisition capabilities and intellectual capital; a $50 million Regulation A+ securities offering to fund its acquisition program; plans to qualify as an Opportunity Fund; and executive changes with appointments such as Willard L. Jackson alongside a ticker change from COBI to BNGI in 2019.